A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of esomeprazole 20 mg and 40 mg once daily oral administration with omeprazole 20 mg once daily oral administration in patients with reflux esophagitis.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esomeprazole (Primary) ; Omeprazole
Indications Reflux oesophagitis
Focus Therapeutic Use
Sponsors AstraZeneca

Most Recent Events

09 Apr 2010 Actual patient number (602) added as reported by ClinicalTrials.gov.
11 Mar 2009 Actual end date reported by ClinicalTrials.gov.
11 Mar 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight